Cullinan Therapeutics Reports Tomorrow But Analysts Haven't Lowered Their Targets
Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Part 2.1: Price Behavior Around Earnings
Cullinan Therapeutics typically reports earnings before market open, meaning Day 0 captures the first full trading session reaction while Day +1 reflects follow-through momentum.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-05-07 | -$0.27 (-1.80%) | $1.04 (6.90%) | -$0.17 (-1.15%) | $0.90 (6.11%) |
| 2026-03-10 | -$0.40 (-2.61%) | $1.46 (9.54%) | -$0.60 (-4.02%) | $0.81 (5.43%) |
| 2025-11-06 | +$0.04 (+0.55%) | $0.76 (10.40%) | -$0.16 (-2.18%) | $0.52 (7.05%) |
| 2025-08-07 | -$0.85 (-10.79%) | $0.85 (10.79%) | +$0.26 (+3.77%) | $0.68 (9.67%) |
| 2025-05-08 | +$0.07 (+0.91%) | $0.42 (5.45%) | -$0.23 (-2.96%) | $0.47 (5.98%) |
| 2025-02-27 | +$0.16 (+1.89%) | $0.44 (5.21%) | -$0.12 (-1.39%) | $0.39 (4.53%) |
| 2024-11-07 | -$0.90 (-5.46%) | $1.82 (11.04%) | +$0.44 (+2.82%) | $0.78 (5.01%) |
| 2024-08-08 | -$0.16 (-0.97%) | $1.50 (9.07%) | +$0.39 (+2.38%) | $1.25 (7.60%) |
| Avg Abs Move | 3.12% | 8.55% | 2.59% | 6.42% |
Historical price action around earnings shows moderate volatility with an average absolute Day 0 move of 3.12% and Day +1 move of 2.59%. The most dramatic reaction came in August 2025, when the stock dropped 10.79% on earnings day following a significant miss, though it partially recovered with a 3.77% gain the following session.
More recently, reactions have been subdued. The March 2026 report saw a 2.61% decline despite a modest beat, while May 2026's beat generated only a 1.80% drop, suggesting investors may be focused more on forward guidance and pipeline updates than quarterly financial performance. The 8.55% average Day 0 range indicates intraday volatility remains elevated even when closing moves are modest, creating both risk and opportunity for traders. Based on this pattern, investors should anticipate a mid-single-digit percentage move in either direction, with the potential for larger swings if results or commentary significantly surprise expectations.
Part 2.2: Options Market Expected Move
| Metric | Value |
|---|---|
| Expiration Date | 08/21/26 (DTE 16) |
| Expected Move | $0.00 (0.00%) |
| Expected Range | $17.64 to $17.64 |
| Implied Volatility | 127.41% |
The options market is currently pricing in a 0.00% expected move for the August 21 expiration, which appears to be a data anomaly given the stock's 127.41% implied volatility and historical earnings moves averaging 3.12%. Based on historical patterns, investors should realistically expect a move in the 3-4% range, consistent with recent earnings reactions.
Part 3: What Analysts Are Saying
Analysts maintain an overwhelmingly bullish stance on Cullinan Therapeutics heading into earnings. The consensus rating stands at 4.86 out of 5.0, with 13 Strong Buy ratings, 0 Moderate Buys, 1 Hold, and no Sell ratings among the 14 analysts covering the stock. This represents one of the most concentrated bullish views in the biotech sector.
The average price target of $33.64 implies 91% upside from the current price of $17.61, with individual targets ranging from a low of $24.00 to a high of $46.00. The wide target range reflects differing assumptions about pipeline success probabilities and timelines to commercialization, but even the most conservative target suggests 36% upside.
Analyst sentiment has remained unchanged over the past month, indicating stable conviction despite recent market volatility. The consistency of the Strong Buy consensus suggests analysts view current levels as an attractive entry point, likely driven by confidence in upcoming clinical catalysts and the company's ability to execute on its development timeline. The single Hold rating prevents a perfect consensus, but the 13-to-1 ratio of Strong Buys to Holds underscores the Street's conviction in Cullinan's long-term value proposition.
Part 4: Technical Picture
Cullinan Therapeutics enters earnings with strong technical momentum across all timeframes. The Barchart Technical Opinion currently stands at 96% Buy, up from 88% Buy one week ago and down slightly from 100% Buy one month ago, indicating sustained bullish sentiment with minor recent consolidation.
Timeframe Analysis:
- Short-term (100% Buy): Maximum bullish signal indicates powerful near-term momentum heading into the earnings release
- Medium-term (100% Buy): Continued strength in the intermediate timeframe suggests the uptrend is well-established beyond just short-term trading
- Long-term (100% Buy): Perfect long-term reading reflects a structural uptrend with strong institutional support
Trend Characteristics: The combination of Strong strength and Strongest direction indicates CGEM is in a robust uptrend with powerful momentum, providing a supportive technical backdrop for the earnings event.
The stock is trading above all major moving averages, including the 5-day ($17.09), 10-day ($17.19), 20-day ($17.46), 50-day ($16.48), 100-day ($15.34), and 200-day ($13.19). This alignment represents a classic bullish setup, with each successively longer-term average below the current price, confirming trend strength across multiple timeframes.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $17.09 | 50-Day MA | $16.48 |
| 10-Day MA | $17.19 | 100-Day MA | $15.34 |
| 20-Day MA | $17.46 | 200-Day MA | $13.19 |
The current price of $17.61 sits just above the 20-day moving average of $17.46, suggesting the stock is testing near-term support after a strong run. The 33% gain above the 200-day moving average ($13.19) reflects substantial appreciation over the past year, potentially leaving the stock vulnerable to profit-taking if earnings disappoint. However, the perfect alignment of moving averages and unanimous Buy signals across all timeframes suggest any pullback would likely find support. The technical setup is supportive heading into earnings, though the magnitude of the recent advance means expectations are elevated and the stock may need a strong beat or positive pipeline update to extend gains.